aspirin and Macular Edema

aspirin has been researched along with Macular Edema in 12 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Macular Edema: Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)

Research

Studies (12)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Change in Area of Retinal Capillary Non-perfusion Outside of the Macula

Change in area of retinal capillary non-perfusion outside of the macula from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks

Change in Area of Retinal Capillary Non-perfusion Within the Macula

Change in area of retinal capillary non-perfusion within the macula compared to baseline, as assessed by ultrawide-field fluorescein angiogram from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks

Change in Area of Total Retinal Capillary Non-perfusion, as Assessed by the Central Reading Center

Change in area of total retinal capillary non-perfusion, as assessed by the central reading center, at week 52 and week 100 compared to baseline. (NCT02863354)
Timeframe: 52 weeks and 100 weeks

Change in Early Treatment of Diabetic Retinopathy Severity Best Corrected Visual Acuity

Mean change in Early Treatment of Diabetic Retinopathy Study Best Corrected Visual Acuity (ETDRS-BCVA) from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks

Changes in Visual Function Outcomes (Self Reported Visual Function)

Changes in self reported visual function utilizing the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) from baseline to week 52 and week 100. The NEI VFQ is a validated measure of patient-reported visual function measured on a scale from 0 (worst function) to 100 (best function). (NCT02863354)
Timeframe: 52 weeks and 100 weeks

Mean Change in Central Subfield Thickness

Mean change in central subfield thickness (CST) from baseline to week 52 and week 100 (NCT02863354)
Timeframe: 52 weeks and 100 weeks

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

• Assess the safety and tolerability of IAI for the treatment of proliferative diabetic retinopathy by evaluating the incidence and severity of ocular and systemic adverse events through week 52 and week 100. (NCT02863354)
Timeframe: 52 and 100 weeks

Percentage of Subjects Treated With Pan-retinal Photocoagulation or Vitrectomy

Percentage of subjects treated with PRP or vitrectomy for progression of PDR from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks

Percentage of Subjects Who Develop Center-involving Diabetic Macular Edema

Percentage of subjects, at week 52 and week 100, who develop center-involving diabetic macular edema who did not have center-involving diabetic macular edema at baseline (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks

Percentage of Subjects Who Develop Vitreous Hemorrhage

Percentage of subjects who develop vitreous hemorrhage from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks

Percentage of Subjects With Increased Neovascularization

Percentage of subjects with increased neovascularization from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks

Percentage of Subjects With Neovascularization Regression

Percentage of subjects with neovascularization regression (reduced area of neovascularization) as measured by the central image reading center from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks

Trials

7 trials available for aspirin and Macular Edema

Other Studies

5 other studies available for aspirin and Macular Edema